In a notable move, Hims & Hers Health donated $1 million to President-elect Donald Trump’s inauguration fund, signaling its ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, ...

Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face ...

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.

The value proposition in contemporary health and disease care: A study published in the Canadian Journal of Cardiology into the cost-effectiveness of the use of semaglutide in overweight or obese ...

Madrigal Pharmaceuticals' strong launch is confirmed with impressive sales in Q1 and Q2. Learn why MDGL stock could benefit ...

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, ...

Hims has become a leader in the weight loss treatment industry by offering access to men’s health solutions that are both ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

"The Republican Party will not cut benefits," Republican House Speaker Mike Johnson said. Also in the news: Medicare drug price negotiations, the House transgender bathroom ban, and more.